Two new studies show that statins, which have been shown to improve survival outcomes in patients with prostate cancer, can help fight off other cancers as well. The studies were presented at Digestive Disease Week 2005 in Chicago. For the studies, data were collected on 484,226 patients from October 1998 to June 2004. The medical records of all patients were studied to determine the effect of statins on pancreatic and esophageal cancer. The researchers found that the risk of developing pancreatic cancer was reduced by 59% among those taking statins, and the risk of esophageal cancer was cut by 56%. In addition to these 2 studies, other studies involving breast cancer and lung cancer, as well as prostate cancer, have shown encouraging data on statins' value in fighting these diseases. Using the same database as the other studies, the researchers found that the risks of developing these cancers were reduced by 51% (breast), 48% (lung), and 54% (prostate) in patients using statins.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs